UK's NuCana Q1 net loss widens; cash runway extends to 2029

NuCana

14/05/2026 23:06

Overview

UK biopharma firm's Q1 net loss widened yr/yr

Company received FDA IND clearance for NUC-7738, with initial studies to focus on melanoma

Cash runway expected to fund operations into 2029

Outlook

Company expects to report final data from Phase 2 NUC-7738 study in melanoma in 2026

NuCana anticipates cash resources will fund operations into 2029

Company plans to seek FDA guidance on potential registrational strategy for NUC-7738 in melanoma

Result Drivers

R&D SPENDING - Higher research and development expenses contributed to the wider net loss in Q1

PIPELINE ADVANCEMENT - Co continued enrollment in Phase 2 study of NUC-7738 in combination with pembrolizumab for melanoma

REGULATORY MILESTONE - FDA IND clearance for NUC-7738 enables U.S. clinical studies, with initial focus on melanoma

Company press release: ID:nGNX8Vb6z5

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Net Income
-GBP 3.90 mln


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)